A phase I/II study of weekly intraperitoneal (IP) paclitaxel (PAC) with monthly intravenous (IV) carboplatin (CBDCA) for optimal debulked epithelial ovarian cancer (EOC) with peritoneal disease (PED)

5120 Background: Although taxane-platinum regimens improved the response rate (RR) in treatment of EOC, long survival has not been obtained due to uncontrollable PED. IP is thought to be one of the...